Medigene AG (Medigene AG) Other Long-Term Liabilities : $1.56 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Medigene AG Other Long-Term Liabilities?

Medigene AG's other long-term liabilities for the quarter that ended in Dec. 2023 was $1.56 Mil.

Medigene AG's quarterly other long-term liabilities declined from Dec. 2022 ($4.76 Mil) to Jun. 2023 ($3.92 Mil) and declined from Jun. 2023 ($3.92 Mil) to Dec. 2023 ($1.56 Mil).

Medigene AG's annual other long-term liabilities increased from Dec. 2021 ($3.94 Mil) to Dec. 2022 ($4.76 Mil) but then declined from Dec. 2022 ($4.76 Mil) to Dec. 2023 ($1.56 Mil).

Medigene AG Other Long-Term Liabilities Historical Data

The historical data trend for Medigene AG's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigene AG Other Long-Term Liabilities Chart

Medigene AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Medigene AG Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Other Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Medigene AG Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Medigene AG Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Medigene AG's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigene AG (Medigene AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (OTCPK:MDGEF) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

MDG1:Germany MDG1:Austria

Address

Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.medigene.com

Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.

Medigene AG (Medigene AG) Headlines

From GuruFocus

Roivant and Sinovant Launch Cytovant Sciences in Partnership with Medigene to Develop Cellular Therapies in Asia

By PRNewswire PRNewswire • 04-04-2019